Sciele And Addrenex Seek Hypertension Approval For Sustained-Release Clonidine
This article was originally published in The Pink Sheet Daily
Executive Summary
The 12-hour formulation is designed to improve clonidine’s side effect profile.
You may also be interested in...
Sciele, Addrenex Partner On Novel Hypertension Drug
Alpha adrenergic receptor agonist will enter Phase II clinical studies in the second half of the year.
Sciele, Addrenex Partner On Novel Hypertension Drug
Alpha adrenergic receptor agonist will enter Phase II clinical studies in the second half of the year.
Sciele Pharma Will Market Clonicel Under Addrenex Deal
Addrenex will submit NDA for sustained-release clonidine for hypertension later this year, followed by application for ADHD.